Although we were not allowed to get enough tissues to isolate hADSC from MSL patients, our findings suggest that the RhoA/ROCK1/ERK1/2 signaling pathway is a potential therapeutic target for the development of drugs that prevent or treat MSL or obesity patients. Here, RHOA is linked to obesity due to melanocortin 4 receptor deficiency.